Background: Gaps in our understanding of genetic susceptibility to malignant hyperthermia (MH) limit the application and interpretation of genetic diagnosis of the condition. Our aim was to define the prevalence and role of variants in the three genes implicated in MH susceptibility in the largest comprehensively phenotyped MH cohort worldwide. Methods: We initially included one individual from each positive family tested in the UK MH Unit since 1971 to detect variants in RYR1, CACNA1S, or STAC3. Screening for genetic variants has been ongoing since 1991 and has involved a range of techniques, most recently next generation sequencing. We assessed the pathogenicity of variants using standard guidelines, including family segregation studies. The prevalence of recurrent variants of unknown significance was compared with the prevalence reported in a large database of sequence variants in low-risk populations. Results: We have confirmed MH susceptibility in 795 independent families, for 722 of which we have a DNA sample. Potentially pathogenic variants were found in 555 families, with 25 RYR1 and one CACNA1S variants previously unclassified recurrent variants significantly over-represented (P<1Â10 À7 ) in our cohort compared with the Exome Aggre-
Editor's key points
Malignant hyperthermia (MH) is a crucially important condition in anaesthetic practice. Accurate diagnosis of MH is challenging. This paper describes the prevalence of known gene variants associated with MH. This knowledge will assist prospective genetic diagnosis.
Malignant hyperthermia (MH) is a potentially fatal reaction that occurs in genetically susceptible individuals exposed to the volatile anaesthetics or succinylcholine. 1 There has been considerable progress in elucidating the genetic basis of MH susceptibility over the past 30 yr. 2 The RYR1 gene that encodes the skeletal muscle sarcoplasmic reticulum calcium release channel was the first gene linked to MH susceptibility 3, 4 and is involved in 34e86% of cases reported. 5e12 RYR1 is a large gene and many variants have been associated with MH susceptibility, although only a minority of these have been demonstrated to be pathogenic. 2 The second gene with variants pathogenic for MH susceptibility is CACNA1S, 13, 14 which encodes the main subunit of the skeletal muscle T-tubule voltage sensor. STAC3 encodes a protein involved in trafficking the voltage sensor into the correct T-tubular location and subsequently a direct role in excitationecontraction coupling: 15, 16 homozygous inheritance of the STAC3 variant p.Trp284Ser leads to a congenital myopathy associated with MH susceptibility. 17 Such findings have enabled limited application of genetic diagnoses, 18 but further expansion has been constrained by the difficulty in establishing a pathogenic role for rare missense variants 19 and evidence that a simple genetic model may not apply in at least a significant minority of cases. 20 Our aims were to define the prevalence of individual variants in RYR1, CACNA1S, and STAC3 in the largest cohort of phenotypically characterised MH susceptible individuals to date, and to assess their likely pathogenicity. We also present data on the proportion of families where there is evidence for more than one genetic variant contributing to MH susceptibility and the proportion where variants in RYR1, CACNA1S, and STAC3 have been excluded.
Methods

Patients
We included index cases or, where the index case could not be tested, their nearest relative from families where MH susceptibility had been confirmed after a clinical reaction suggestive of MH. We excluded cases referred where there had been no adverse anaesthetic event, such as those patients referred with a history of exertional heat illness, exertional or recurrent rhabdomyolysis, or a congenital myopathy. MH susceptibility was confirmed by in vitro contracture testing (IVCT) or finding of a functionally characterised genetic variant pathogenic for MH susceptibility. The criteria used for diagnosis of MH susceptibility were those of the European MH Group applicable at the time of diagnosis. 18, 21, 22 
Detection of genetic variants
This was as described by Merritt and colleagues. 19 In brief, we began screening MH susceptible families for RYR1 variants after publication of the first RYR1 variant implicated in MH susceptibility. 23 As further RYR1 variants were reported, we undertook a systematic search for all published variants principally using amplification refractory mutation system or restriction digest assays. As technology developed, we used Sanger sequencing of mutation 'hot-spots' and then the whole coding region of RYR1 and CACNA1S. 
Family studies
When potentially pathogenic variants are identified in a family, a segregation study of the variant is undertaken for those individuals who have been phenotyped by IVCT. Again, depending on when the study was done and the nature of the variant, this was either using an amplification refractory mutation system test, a restriction digest assay, or direct sequencing. When we encountered a case of discordance between familial variant and IVCT, we reviewed the IVCT records (phenotype) and calculated the probability that the IVCT responses represented an abnormal response. 25 We also verified the genotype using Sanger sequencing where a DNA sample was available and, again when feasible, used deep resequencing of RYR1 and CACNA1S to look for alternative diseaseassociated variants in cases of affected non-carriers.
Variant prevalence in MH families and the general population
We defined the prevalence in the UK MH population as the number of independent families carrying a variant divided by the number of independent MH families in whom genetic analysis has been undertaken. For an estimate of the population prevalence of each variant, we used data presented in the ExAC browser (http://exac.broadinstitute.org) for the European non-Finnish cohort, unless our cases were from a nonwhite ethnic background in which case the appropriate ExAC population was used.
In silico assessment of pathogenicity of variants
For each variant, we obtained the C-score from http://cadd.gs. washington.edu (accessed 18 March 2018). The C-score is derived from Combined Annotation-Dependent Depletion and scores of >15 include the 5% predicted most deleterious substitutions in the human genome. 26 Because of the uncertainty of the validity of using in silico tools for prediction of pathogenicity of RYR1 variants, 27 we simply report the values rather than using them to infer likelihood of pathogenicity.
Statistical analysis
We compared the prevalence estimates for potentially path- ). As we had selected our genes of interest in a non-random way from~20 000 genes in the genome, and because we made comparisons for multiple variants, we used a P value <1Â10 À7 to infer statistical significance.
Results
A total of 770 independent families with MH confirmed by a positive IVCT after a clinical episode consistent with MH susceptibility were identified. DNA samples were available from at least one member of 697 families. Pathogenic RYR1 variants have been identified by NGS in the probands of a further 25 families since the introduction of NGS as a primary diagnostic test.
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Variants in the RYR1 gene
One hundred and forty-seven different potentially pathogenic variants were found in at least one independent MH family and these are listed in Supplementary Table S1 . Of these, 31 have been previously sufficiently characterised to be used in prospective diagnosis (www.emhg.org). A further 29 of the 147 potentially pathogenic variants were found in more than one family. These are presented in Table 1 , along with the population prevalence in the ExAC browser. The difference in prevalence between the UK MH cohort and the relevant ExAC browser cohort was statistically significant for 25 of these 29 variants (Table 1 ). All of these variants were found in the heterozygous state except p.Arg3772Gln which we have previously reported in three of the six families listed in Table 1 . 28 In total, 546 of 722 families carry at least one pathogenic, likely pathogenic, or potentially pathogenic RYR1 variant. ) and meets our criteria for classifying it as likely pathogenic.
Variants in the CACNA1S gene
The p.Arg1086Ser variant has previously been reported in association with MH 32 and involves substitution of the same several of our potentially pathogenic CACNA1S variants were found in patients with a non-white ethnic background. Both patients with the p.Arg174Trp variant were black/African/ Caribbean, although this variant was not found in any of 10 376 alleles in the ExAC African cohort. In addition to p.Arg1086Ser, three further variants were found only in patients of South Asian origin. Two of these, p.Pro758Leu and p.Leu885Pro, were found in the same patient, while p.His992Asp was also present in a single patient. The prevalence for each of these variants in the ExAC South Asian cohort was less than one in 1000 and so these variants remain potentially pathogenic. One of the CACNA1S variants meeting our criteria for being potentially pathogenic in MH, p.Arg900Ser, has previously been reported in association with hypokalaemic periodic paralysis. 33 This and another CACNA1S variant, p.Gly1210Arg, were found in a patient who we have previously reported 34 with a history of hypokalaemic periodic paralysis and MH, and the RYR1 c.7025A>G, p.Asn2342Ser variant. Four other families with potentially pathogenic CACNA1S variants also had a potentially pathogenic RYR1 variant. There were seven families with pathogenic or potentially pathogenic CACNA1S variants only.
Variants in the STAC3 gene
We found the previously reported p.Trp284Ser variant in one proband who was homozygous for this variant. This patient was originally from the Middle East. No novel potentially pathogenic variants were found in STAC3. Families where variants in the coding regions of RYR1, CACNA1S, and STAC3 were not found.
We found potentially pathogenic variants in 555 of 722 families. Of the remaining 167 families, RYR1, CACNA1S, and STAC3 were sequenced with NGS in 103 families, with the sequence of regions of low quality reads being confirmed by Sanger sequencing.
Segregation analysis
Segregation between genotype and IVCT phenotype was assessed in 328 families with an RYR1 variant and four families with CACNA1S variants. The median (range) number of MH susceptible and MH normal members included per family was two (1e16) and three (1e27), respectively. In families carrying a pathogenic RYR1 variant there were 72 out of 280 families with at least one example of genotypeephenotype discordance (Table 3) . In families carrying a likely pathogenic RYR1 variant there were 14 out of 48 families with at least one example of genotypeephenotype discordance (Table 4) .
Families with more than one variant
We have identified 27 of 293 families where sequencing of the entire coding regions of the three genes has been done in which more than one potentially pathogenic variant in RYR1, CACNA1S, or STAC3 has been identified. The number of families with two, three, or four such variants was 21, five, and one, respectively.
Discussion
This analysis provides the best estimate to date of the prevalence and distribution of genetic variants in MH susceptible families in a principally European Caucasian population. RYR1 variants were found in 546 of 722 independent families corresponding to an estimate of 76% [95% confidence interval (CI) 72e79%]. We have confirmed the extent of allelic heterogeneity within RYR1 and demonstrated that the majority of RYR1 variants in our population are private to individual families. However, just 28 variants are implicated in >50% of our MH families, with one variant, p.Gly2434Arg, found in almost 16% of MH families. Interestingly, in 434 families we reported in 2006, we identified 52 RYR1 variants of which~50% were private to individual families. 5 Other than our cohort, the largest evaluation of the prevalence of RYR1 variants associated with MH susceptibility included 120 families from the USA 11 of which 62 (52%, 95% CI 43e61%) had RYR1 variants. A total of 96 Australian patients have been included in two reports from Gillies and colleagues 8, 12 and 33 of these were found to carry RYR1 variants cludes an algorithm to determine the classification of individual variants and we have attempted to apply this to the variants we have found. Using this algorithm, recurrent variants that have been functionally characterised using genetic engineering and homologous or heterologous expression systems are classified as pathogenic, but none of our other variants could be classified beyond a variant of unknown significance (potentially pathogenic) despite many being found in multiple MH families but rarely in the control population.
Through comparing the prevalence of recurrent RYR1 variants in our population with that of a relevant low-risk (for MH susceptibility) population presented within the ExAC browser dataset, we have provided compelling statistical evidence that a further 25 RYR1 variants are likely to be pathogenic. We suggest that these are suitable to be used in prospective DNA diagnosis of MH susceptibility within the framework for diagnostic testing recommended by the European MH Group. 18 This framework enables the presence of a likely pathogenic or pathogenic variant to be used to confirm high-risk status, but requires the absence of a familial variant to be confirmed by IVCT in order for a sufficiently low-risk status to be assigned such that the patient may safely receive MH triggering anaesthetics. Addition of these 25 RYR1 variants to the diagnostic panel would enable a further 97 UK MH families to benefit from prospective DNA diagnosis.
Pathogenic or potentially pathogenic CACNA1S variants were found in 12 (1.7%, 95% CI 0.9e2.9%) UK MH families, but five of these families also carried a potentially pathogenic RYR1 variant. Our previous review of RYR1 variants 5 highlighted that the distribution of variants was spread widely across the gene, rather than in three 'hot-spots' previously described. We now report a similar situation in CACNA1S with variants that are at least potentially pathogenic occurring between amino acid positions 174 and 1696 (Table 2) . Furthermore, the variants affect a variety of functional sites within the Ca v 1.1 protein. 37 The p.Arg174 amino acid is one of the positively charged residues of the S4 segment of domain I; the S4 segments are thought to be the voltage sensors of the protein. Mutations of the arginine residues of the S4 segments of domains III (p.Arg900) 35, 38 and IV (p.Arg1239) 39, 40 cause hypokalaemic periodic paralysis, while the p.Arg1242Gly variant (domain IV S4) is associated with normokalaemic periodic paralysis. 41 The p.Asn909Ser found in our cohort also affects the S4 segment of domain III. The amino acid p.Arg1086 is located in the cytoplasmic loop between domains III and IV and this loop has been shown to influence RyR1 channel gating. 42 One of our new variants to be associated with MH susceptibility, p.Pro758Leu, is located in the domain IeII cytoplasmic loop in a region thought to be critical for excitationecontraction coupling. Three of our potentially pathogenic CACNA1S variants, p.Tyr617Ala, p.His992Asp, and p.Thr1009Lys, may affect the Ca v 1.1 channel pore regions of domains II, III, and III respectively. A potential mechanism for pathogenicity of our other CACNA1S variants is less clear. Our single case of homozygous presentation of the p.Trp284Ser STAC3 variant was in a patient from the Middle East. It is interesting that this variant is present in 0.12% of the African ExAC population, suggesting that it did not originate in the Native American population from which the congenital myopathy derived its name. There are no reported cases of MH associated with the presence of this variant in the heterozygous state and indeed the prevalence of the variant in the African population makes this unlikely.
Of 722 families, we have excluded RYR1, CACNA1S, and STAC3 variants in 103 families using NGS. No variants in these genes have been found in a further 64 families, but the genetic analyses of these families have not been so extensive as to conclude that variants in RYR1, CACNA1S, and STAC3 are not present. We can therefore provide a range of estimates for non-RYR1/CACNA1S/STAC3 MH susceptibility of between 14% (95% CI 11.5e17%) and 23% (95% CI 20e26%). As with other groups 43 we have used exome sequencing to search for variants in other genes, 31 but the analytical approach to distinguish potentially pathogenic from benign variants is challenging. 2 We first reported discordance within a family between a functionally relevant RYR1 variant and the IVCT phenotype 20 yr ago. 44 Similar findings have been reported across European laboratories. 20 Since the introduction of predictive testing for familial variants, high risk status indicated by the presence of a familial variant has not been required to be confirmed with subsequent IVCT, which is not the case for low risk status in the absence of a familial variant. There has therefore been an inevitable bias in the type of discordance recorded over the past 15 yr, with only a susceptible phenotype in the absence of a familial variant detected. The occurrence of discordance appears to be distributed equally among the various RYR1 variants, with the number of discordant cases reflecting the number of families harbouring the variant where segregation analyses have been done. The possible exception to this is RYR1 p.Arg2435His where we found no cases of genotypeephenotype discordance in 10 families where segregation analyses had been conducted. It is interesting to note that this variant was found to be associated with one of the 'strongest' IVCT phenotypes. 45 In that paper, we proposed a threshold genetic model for MH susceptibility to explain genotypeephenotype discordance. If this is the case, the extent of genotypeephenotype discordance that we now present could suggest that very few RYR1 variants are sufficiently penetrant to consistently cause MH susceptibility in the absence of other genetic risk factors. Such a situation would be consistent with the high combined prevalence of known pathogenic RYR1 variants. 2 An alternative explanation for genotypeephenotype discordance is errors in either genotyping or phenotyping. The genotypes of all our discordant cases involving pathogenic variants have been confirmed under strict diagnostic laboratory quality control procedures. The IVCT responses of discordant cases have been evaluated using a predictive model 25 to minimise the likelihood of misdiagnosis. We also routinely send a sample of the muscle biopsy for histological and histochemical analyses to exclude muscle pathology as a cause of a false positive IVCT result. 46e48 The number of false positive IVCT results in a cohort of 202 subjects at low risk for MH susceptibility was reported by the European MH Group to be 13 (6.43%). 49 Out of 656 patients who tested negative for a familial mutation, we found 79 (12.04%) to have a positive IVCT phenotype (Tables 3 and 4 ). The difference in these proportions is 5.61% (95% CI 0.78e9.39%, P¼0.024), which further argues against phenotyping error as an explanation for genotypeephenotype discordance. Our hypothesis that genotypeephenotype discordance is a result of the presence of more than one genetic risk factor for MH susceptibility is supported by our finding of more than one potentially pathogenic variant in 9.2% (95% CI 6.2e13.1%) of the 293 families in which RYR1, CACNA1S, and STAC3 had been fully sequenced.
In conclusion, we have described the most comprehensive genetic analysis of MH susceptibility to date. All of the families included have a relevant anaesthetic history and the diagnosis has been confirmed by internationally accepted diagnostic tests. Our data confirm the importance of variants in RYR1 and the high proportion of these that are private to single families. We propose that 25 recurrent RYR1 variants can be used for prospective genetic diagnosis of high risk status for MH susceptibility. The prevalence of potentially pathogenic variants in CACNA1S is slightly higher than previous estimates and our data suggest that their role in non-white populations may be even more important. We present further evidence that not all cases of MH are explained by genetic variants in RYR1, CAC-NA1S, or STAC3 and that combinations of potentially pathogenic variants in these genes are present in a significant minority of MH families. 
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